RSV Immunization Recommended for Most Older Adults

GSK plc today announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the routine use of Respiratory Syncytial Virus (RSV) vaccines in all adults aged 75 and above.

The ACIP also recommended RSV immunization for adults aged 60-74 who are at increased risk for severe RSV disease.

These recommendations replace the previous recommendation for shared clinical decision-making in these age groups and have the potential to positively impact access to RSV immunization, particularly for the estimated 23 million U.S. adults aged 75 and older.

In May 2023, the U.S. FDA approved GSK’s AREXVY™ RSV vaccine, which is currently available at clinics and pharmacies before the 2024-2025 RSV season.

The ACIP recommendations will be forwarded to the director of the CDC and the Department of Health and Human Services for review and approval. Once approved, the final recommendations will be published in a future CDC Morbidity and Mortality Weekly Report.